Abstract
Abstract Background: To assess the viability and averageness of capecitabine joined together with thalidomide in patients with propelled pancreatic disease (APC) who have beforehand accepted gemcitabine-based treatment. Systems: what added up to 31 patients were enrolled prospectively in Shandong Tumor Hospital from May 2007 to April 2009. Capecitabine was offered to patients twice a day at a dosage of 1,250 mg/m2 for 14-days then emulated by 7-day rest. Thalidomide was controlled 100 mg/day without interference until sickness movement or event of inadmissible poisonous quality. Results: Two patients put forth fractional reaction (PR), eleven patients indicated stable ailment (SD) and eighteen patients exhibited continuous illness (PD). The average without movement survival (PFS) was 2.7 months (95% expectancy interim (CI), 2.4-3.3) and the average generally speaking survival (OS) was 6.1 months (95% CI, 5.3-6.9). In the subgroup examination, PFS had a huge distinction between the serum CA19-9 level diminishing >25% and diminishing <25%, with 3.0 months (95% CI, 2.5-3.6) and 2.5 months (95% CI, 1.8-3.2), (Log Rank=0.02), separately. Hematological poisonous quality incorporated leukocytopenia, frailty and neutropenia. Non-hematological toxicities incorporated loose bowels, skin rash, nausea/vomiting, hand-foot syndrome, weariness, discombobulation, languor and clogging. Conclusion: Capecitabine joined together with thalidomide is a generally tolerated second line regimen, in patients with APC obstinate to gemcitabine.
Highlights
Pancreatic malignancy is a regular threatening tumor with downtrodden guess, 5-years survival of 5%, owing to the trouble from distinguishing at an early stage and elevated threatening potential [1]
GEM joined together with oxaliplatin was a cut above that of GEM apart from everyone else regarding clinical profit, reaction rate, movement unhindered survival and a helpful slant in survival of generally 2 months in first-line medication [5]. These days, numerous synthesis medicines of GEM in addition to focused on executors for example bevacizumab, cetuximab and erlotinib have been examined in propelled pancreatic tumor (APC)
Patients with mainly progressed or metastatic pancreatic disease affirmed by histology and cytology, appropriated capecitabine joined together with thalidomide as second-line medicine
Summary
Pancreatic malignancy is a regular threatening tumor with downtrodden guess, 5-years survival of 5%, owing to the trouble from distinguishing at an early stage and elevated threatening potential [1]. GEM joined together with oxaliplatin was a cut above that of GEM apart from everyone else regarding clinical profit, reaction rate, movement unhindered survival and a helpful slant in survival of generally 2 months in first-line medication [5]. These days, numerous synthesis medicines of GEM in addition to focused on executors for example bevacizumab, cetuximab and erlotinib have been examined in propelled pancreatic tumor (APC). Medication with capecitabine brought about clinically critical useful impacts on tumor-identified manifestations and yielded goal reaction movement in patients with generally propelled or metastatic pancreatic disease. Thalidomide was controlled 100 mg/day without interference until sickness movement or event of inadmissible poisonous quality
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call